Back to Blog
Outset medical6/11/2023 ![]() On May 4, 2022, after markets closed, Outset announced disappointing financial results for the first quarter of 2022, which analysts attributed in part to Tablo’s untested performance in the home setting. Food and Drug Administration (“FDA”) (2) in the absence of such studies and FDA approval, the Company could not conduct a human factors study on the Tablo pursuant to FDA protocols and (3) Outset’s inability to conduct the human factors study exposed the Company to the risk of FDA actions, including a shipping hold and marketing suspension, rendering Outset incapable of selling Tablo for home use. The action alleges that, throughout the Class Period, Outset misled investors and/or failed to disclose that: (1) the Company had “continuously made improvements and updates to Tablo over time since its original clearance,” which required further studies and potentially new applications to the U.S. Outset, headquartered in San Jose, California, is a medical technology company whose chief product, the Tablo Hemodialysis System (“Tablo”), is used for the treatment of acute and chronic kidney failure. Portnoy, by phone 84 or email: to discuss their legal rights, or click here to join the case via The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses. Investors are encouraged to contact attorney Lesley F. Outset investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. (“Outset” or the “Company”) (Nasdaq: OM) investors that a class action has been filed on behalf of investors. ![]() 07, 2022 (GLOBE NEWSWIRE) - The Portnoy Law Firm advises Outset Medical, Inc. Investors can contact the law firm at no cost to learn more about recovering their losses ![]()
0 Comments
Read More
Leave a Reply. |